A NEXTGEN DRUG DEVELOPMENT COMPANY
Falcon Creek is an investment portfolio company focused on developing novel drug candidates. Our emphasis is on using artificial intelligence (AI), digital chemistry, quantum physics, and robotics to accelerate new therapeutic options for patients with unmet needs.
OVERVIEWYour strategic partner for accelerating drug discovery and development.
|
|
Headquartered in Boston, Massachusetts, Falcon Creek Capital was founded in 2019. Our team includes seasoned investors and pharmaceutical executives with extensive experience managing dynamic investment portfolios. The firm specializes in cutting-edge biotechnology investments and complex business management solutions.
Falcon Creek Capital and its partners serve as the General Partner for several funds, including Coalescence Special Situation Fund I, Falcon Creek Biotech Venture Fund, Aceso Biotech Venture Fund, and Plaisance Capital Management LLC, which oversees the Plaisance Venture Fund. Our clients include family offices, high-net-worth individuals, and foundations. Collectively, the firm's partners have managed over $3 billion in investment assets over the course of their careers.